Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.6.1.54: UDP-2,3-diacylglucosamine diphosphatase

This is an abbreviated version!
For detailed information about UDP-2,3-diacylglucosamine diphosphatase, go to the full flat file.

Word Map on EC 3.6.1.54

Reaction

a UDP-2-N,3-O-bis[(3R)-3-hydroxyacyl]-alpha-D-glucosamine
+
H2O
=
a lipid X
 +
UMP

Synonyms

LpxH, LpxI, UDP-2, 3-diacylglucosamine hydrolase, UDP-2,3-bis[(3R)-3-hydroxymyristoyl]-alpha-D-glucosamine 2,3-bis[(3R)-3-hydroxymyristoyl]-beta-D-glucosaminyl 1-phosphate phosphohydrolase, UDP-2,3-diacylglucosamine hydrolase, UDP-2,3-diacylglucosamine pyrophosphatase, UDP-2-N,3-O-bis[(3R)-3-hydroxytetradecanoyl]-alpha-D-glucosamine 2-N,3-O-bis[(3R)-3-hydroxytetradecanoyl]-alpha-D-glucosaminyl 1-phosphate phosphohydrolase, UDP-diacylglucosamine pyrophosphatase, UDP-diacylglucosamine pyrophosphohydrase, UDP-diacylglucosamine pyrophosphohydrolase, YbbF

ECTree

     3 Hydrolases
         3.6 Acting on acid anhydrides
             3.6.1 In phosphorus-containing anhydrides
                3.6.1.54 UDP-2,3-diacylglucosamine diphosphatase

Inhibitors

Inhibitors on EC 3.6.1.54 - UDP-2,3-diacylglucosamine diphosphatase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1-(5-((4-(3-(trifluoromethyl) phenyl)piperazin-1-yl) sulfonyl)indolin-1-yl)ethan-1-one
47.2% residual activity at 0.002 mM, 23.5% residual activity at 0.006 mM, 14.1% residual activity at 0.01 mM, 11.7% residual activity at 0.05 mM
1-(5-[4-[3-(propan-2-yl)phenyl]piperazine-1-carbonyl]-2,3-dihydro-1H-indol-1-yl)ethan-1-one
-
29% residual activity at 0.01 mM
1-(5-[4-[3-(trifluoromethyl)phenyl]-1,4-diazepane-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl)ethan-1-one
-
94% residual activity at 0.01 mM
1-(5-[4-[3-(trifluoromethyl)phenyl]piperazine-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl)ethan-1-one
-
6.0% residual activity at 0.01 mM
1-[5-(4-phenylpiperazine-1-sulfonyl)-2,3-dihydro-1H-indol-1-yl]ethan-1-one
-
32% residual activity at 0.01 mM
1-[5-(4-[[3-(trifluoromethyl)phenyl]methyl]piperazine-1-carbonyl)-2,3-dihydro-1H-indol-1-yl]ethan-1-one
-
87% residual activity at 0.01 mM
1-[5-[4-(3-bromophenyl)piperazine-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl]ethan-1-one
-
24% residual activity at 0.01 mM
1-[5-[4-(3-ethylphenyl)piperazine-1-carbonyl]-2,3-dihydro-1H-indol-1-yl]ethan-1-one
-
21% residual activity at 0.01 mM
1-[5-[4-(3-hydroxyphenyl)piperazine-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl]ethan-1-one
-
91% residual activity at 0.01 mM
1-[5-[4-([1,1'-biphenyl]-3-yl)piperazine-1-carbonyl]-2,3-dihydro-1H-indol-1-yl]ethan-1-one
-
24% residual activity at 0.01 mM
2-oxo-2-((4-((4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)sulfonyl)phenyl)amino)acetic acid
-
55% residual activity at 0.01 mM
3-[4-[3-(trifluoromethyl)phenyl]piperazine-1-sulfonyl]benzoic acid
-
98% residual activity at 0.01 mM
4-[5-[4-(3-bromophenyl)piperazine-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl]-4-oxobutanoic acid
-
24% residual activity at 0.01 mM
EDTA
complete inhibition at 2 or 0.2 mM
methyl 4-[5-[4-(3-bromophenyl)piperazine-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl]-4-oxobutanoate
-
42% residual activity at 0.01 mM
N-(4-((4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)sulfonyl)phenyl)acetamide
-
36% residual activity at 0.01 mM
N-(4-[4-[3-(trifluoromethyl)phenyl]piperazine-1-sulfonyl]phenyl)acetamide
-
30% residual activity at 0.01 mM
N1-hydroxy-N2-(4-((4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)sulfonyl)phenyl)oxalamide
-
41% residual activity at 0.01 mM
Triton X-100
0.01%